Search
Fomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnAs a complementary nucleotide to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, it disrupts the replication of the virus through an antisense mechanism [L1428] … Fomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA).
Categories: Compounds used in a research, industrial, or household settingHexocyclium
go.drugbank.com/drugs/DB06787ApprovedHexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more
Categories: Heterocyclic Compounds, 1-RingMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. … linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesVenlafaxine
go.drugbank.com/drugs/DB00285ApprovedInvestigational[L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. … for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein inhibitorsProducts: VENLAVITAE® 75 MG CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA, VENOXOR®75 MGEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998] … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingElamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigational[A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane. … [L54036] In September 2025, the U.S.
Categories: MATE 1 InhibitorsFosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalFosnetupitant is the pro-drug form of netupitant [FDA label]. … Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Cytochrome P-450 CYP3A InhibitorsBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnBelantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). … [L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331]
Categories: P-glycoprotein substratesBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnIt is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). … A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects.
Synonyms: 1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE, 1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesElivaldogene autotemcel
go.drugbank.com/drugs/DB16746ApprovedIt was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder. … [A243691] ALDP is a key protein that normally breaks down fatty substances in the body called very long-chain fatty acids (VLCFAs).
International brands: Lenti-D